ADVATE 2000 IU and 3000 IU powder and solvent for solution for injection 5 ml water - Baxject III
- Name:
ADVATE 2000 IU and 3000 IU powder and solvent for solution for injection 5 ml water - Baxject III
- Company:
Shire Pharmaceuticals Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 15/04/20
(Click to Download)Click on this link to Download PDF directly
Shire Pharmaceuticals Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 15 April 2020 PIL
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 15 April 2020
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Updated on 15 April 2020 PIL
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - marketing authorisation number
- Change to section 6 - date of revision
Updated on 15 April 2020
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 7 - Marketing authorisation holder
Updated on 4 March 2020
Reasons for updating
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Updated on 4 March 2020
Reasons for updating
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Updated on 2 March 2020 PIL
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 2 March 2020
Reasons for updating
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Updated on 17 September 2018
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Free text change information supplied by the pharmaceutical company
Section 5.1 (Pharmacodynamic properties), updated with the rewording of information regarding Immune Tolerance Induction (ITI)
Updated on 15 August 2018 PIL
Reasons for updating
- Change to section 4 - how to report a side effect
Updated on 14 August 2018 PIL
Reasons for updating
- Change to date of revision
Updated on 14 August 2018
Reasons for updating
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Section 10 (date of revision of thew text), updated. Change to the joint SPC with UK - ADR statement for UK was updated accoriding to QRD template.
Updated on 14 August 2018
Reasons for updating
- Change to section 4.2 - Posology and method of administration
Free text change information supplied by the pharmaceutical company
Section 4.2 (Posology and method of administration), deletion of specific information that the use of 2 ml presentations has not been documented for paediatric subjects below 2 years of age.
Updated on 19 December 2017
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 19 December 2017 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
- In section 4.4 (Special warnings and precautions for use), updated with scientific information on inhibitors.
- In section 4.8 (undesirable effects), updated with scientific information on inhibitors.
- In section 5.1 (Pharmacodynamic properties), removed scientific information on inhibitor development.
- In section 9 (DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION), updated with the latest renewal date.
Updated on 14 December 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 14 December 2017 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 6 July 2017 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 12 February 2016 SPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may not be renewed (A)